In both studies, upadacitinib met the coprimary endpoints of T-VASI 50 and F-VASI 75 at week 48 vs placebo. Topline data were announced from 2 replicate phase 3 studies evaluating upadacitinib in ...

MONTREAL, Aug. 27, 2025 /CNW/ - AbbVie today announced that Health Canada has issued a Notice of Compliance for RINVOQ ® (upadacitinib) for the treatment of adults with giant cell arteritis (GCA), ...

Study 1 results showed 45.2% and 55.0% of patients treated with upadacitinib 15mg and 30mg, respectively, achieved the primary endpoint at 24 weeks compared with 1.5% of those receiving placebo.

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with ...

BARCELONA, Spain — The JAK inhibitor upadacitinib can effectively treat systemic sclerosis-associated interstitial lung disease (SSc-ILD), according to results from a new clinical trial. Patients ...

Upadacitinib (Rinvoq), a selective Janus kinase 1 (JAK1) inhibitor, is an emerging treatment for inflammatory bowel disease (IBD) and is increasingly used in clinical practice. Real-world data suggest ...

Upadacitinib shows sustained efficacy in UC, with over half maintaining clinical remission through 144 weeks in a phase 3 LTE study. Real-world data from the IBD-DACH study confirmed upadacitinib's ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The study was an open-label extension of two phase 3 ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...

Upadacitinib, a JAK1 inhibitor, is effective for inflammatory conditions but may induce alopecia areata in some patients. A case study reported alopecia areata in a patient after nearly a year of ...

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and WP-NRS 0/1 at week 16. Among patients with moderate to severe atopic ...

Two invalidation decisions involving the US pharmaceutical company provide guidance on the building of a patent portfolio in China and the filing of supplementary experimental evidence, says Yue Guan ...